<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26475924</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1550-6606</ISSN><JournalIssue CitedMedium="Internet"><Volume>195</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of immunology (Baltimore, Md. : 1950)</Title><ISOAbbreviation>J Immunol</ISOAbbreviation></Journal><ArticleTitle>A Central Role for HLA-DR3 in Anti-Smith Antibody Responses and Glomerulonephritis in a Transgenic Mouse Model of Spontaneous Lupus.</ArticleTitle><Pagination><StartPage>4660</StartPage><EndPage>4667</EndPage><MedlinePgn>4660-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1501073</ELocationID><Abstract><AbstractText>MHC, especially HLA-DR3 and HLA-DR2, is one of the most important genetic susceptibility regions for systemic lupus erythematosus. Human studies to understand the role of specific HLA alleles in disease pathogenesis have been hampered by the presence of strong linkage disequilibrium in this region. To overcome this, we produced transgenic mice expressing HLA-DR3 (DR&#x3b2;1*0301) and devoid of endogenous class II (both I-A and I-E genes, AE(0)) on a lupus-prone NZM2328 background (NZM2328.DR3(+)AE(0)). Both NZM2328 and NZM2328.DR3(+)AE(0) mice developed anti-dsDNA and glomerulonephritis, but anti-dsDNA titers were higher in the latter. Although kidney histological scores were similar in NZM2328 and NZM2328.DR3(+)AE(0) mice (7.2 &#xb1; 4.3 and 8.6 &#xb1; 5.7, respectively, p = 0.48), the onset of severe proteinuria occurred earlier in NZM2328.DR3(+)AE(0) mice compared with NZM2328 mice (median, 5 and 9 mo respectively, p &lt; 0.001). Periarterial lymphoid aggregates, classic wire loop lesions, and occasional crescents were seen only in kidneys from NZM2328.DR3(+)AE(0) mice. Interestingly, NZM2328.DR3(+)AE(0) mice, but not NZM2328 mice, spontaneously developed anti-Smith (Sm) Abs. The anti-Sm Abs were seen in NZM2328.DR3(+)AE(0) mice that were completely devoid of endogenous class II (AE(-/) (-)) but not in mice homozygous (AE(+/+)) or heterozygous (AE(+/-)) for endogenous MHC class II. It appears that only HLA-DR3 molecules can preferentially select SmD-reactive CD4(+) T cells for generation of the spontaneous anti-Sm immune response. Thus, our mouse model unravels a critical role for HLA-DR3 in generating an autoimmune response to SmD and lupus nephritis in the NZM2328 background.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 by The American Association of Immunologists, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chowdhary</LastName><ForeName>Vaidehi R</ForeName><Initials>VR</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905; chowdhary.vaidehi@mayo.edu sf2e@virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center of Immunity, Inflammation, and Regenerative Medicine, Department of Medicine, University of Virginia, Charlottesville, VA 22908;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilahun</LastName><ForeName>Ashenafi Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN 55905;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN 55905;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smart</LastName><ForeName>Michele K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Infectious Diseases Research, Mayo Clinic College of Medicine, Rochester, MN 55905;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grande</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Anatomic Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajagopalan</LastName><ForeName>Govindarajan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN 55905;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Shu-Man</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-5158-3494</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905; Center of Immunity, Inflammation, and Regenerative Medicine, Department of Medicine, University of Virginia, Charlottesville, VA 22908; Division of Rheumatology, Department of Medicine, School of Medicine, University of Virginia, Charlottesville, VA 22908; and Department of Microbiology, Immunology, and Cancer Biology, School of Medicine, University of Virginia, Charlottesville, VA 22908 chowdhary.vaidehi@mayo.edu sf2e@virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Chella S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN 55905;</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AR-057815</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23-AR057815</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AR049449</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR030752</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AR30752</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR049449</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR047988</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AR047988</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AR057815</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Immunol</MedlineTA><NlmUniqueID>2985117R</NlmUniqueID><ISSNLinking>0022-1767</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015802">HLA-DR2 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015803">HLA-DR3 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C553502">HLA-DRB1*03:01 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055517">snRNP Core Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005921" MajorTopicYN="N">Glomerulonephritis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015802" MajorTopicYN="N">HLA-DR2 Antigen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015803" MajorTopicYN="N">HLA-DR3 Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="N">Lupus Nephritis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055517" MajorTopicYN="N">snRNP Core Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no financial conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26475924</ArticleId><ArticleId IdType="mid">NIHMS796900</ArticleId><ArticleId IdType="pmc">PMC5292932</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1501073</ArticleId><ArticleId IdType="pii">jimmunol.1501073</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, Straaton KV, Alarc&#xf3;n GS. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum. 1998;41:1161&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">9663471</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Urowitz MB, Darlington GA. Disease expression and class II HLA antigens in systemic lupus erythematosus. Lupus. 1999;8:466&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">10483016</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham RR, Ortmann WA, Langefeld CD, Jawaheer D, Selby SA, Rodine PR, Baechler EC, Rohlf KE, Shark KB, Espe KJ, et al. Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erythematosus. Am. J. Hum. Genet. 2002;71:543&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379191</ArticleId><ArticleId IdType="pubmed">12145745</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley JB, Alarc&#xf3;n-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 2008;40:204&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712260</ArticleId><ArticleId IdType="pubmed">18204446</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham RR, Ortmann W, Rodine P, Espe K, Langefeld C, Lange E, Williams A, Beck S, Kyogoku C, Moser K, et al. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur. J. Hum. Genet. 2007;15:823&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406641</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters ST, Fu SM, Gaskin F, Deshmukh US, Sung SS, Kannapell CC, Tung KS, McEwen SB, McDuffie M. NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin. Immunol. 2001;100:372&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">11513551</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters ST, McDuffie M, Bagavant H, Deshmukh US, Gaskin F, Jiang C, Tung KS, Fu SM. Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J. Exp. Med. 2004;199:255&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211766</ArticleId><ArticleId IdType="pubmed">14718514</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim DL, Bagavant H, Scindia YM, Ge Y, Gaskin F, Fu SM, Deshmukh US. Genetic complementation results in augmented autoantibody responses to lupus-associated antigens. J. Immunol. 2009;183:3505&#x2013;3511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837801</ArticleId><ArticleId IdType="pubmed">19667095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirose S, Zhang D, Nozawa S, Nishimura H, Shirai T. The E-linked subregion of the major histocompatibility complex down-regulates autoimmunity in NZB &#xd7; NZW F1 mice. Immunogenetics. 1994;40:150&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">8026863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong YC, Lomo LC, Motte RW, Giraldo AA, Baisch J, Strauss G, H&#xe4;mmerling GJ, David CS. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J. Exp. Med. 1996;184:1167&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192804</ArticleId><ArticleId IdType="pubmed">9064334</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss G, Vignali DA, Sch&#xf6;nrich G, H&#xe4;mmerling GJ. Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice. Immunogenetics. 1994;40:104&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">8026858</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen L, Labrecque N, Engberg J, Dierich A, Svejgaard A, Benoist C, Mathis D, Fugger L. Mice lacking all conventional MHC class II genes. Proc. Natl. Acad. Sci. USA. 1999;96:10338&#x2013;10343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17889</ArticleId><ArticleId IdType="pubmed">10468609</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhary VR, Grande JP, Luthra HS, David CS. Characterization of haemorrhagic pulmonary capillaritis: another manifestation of Pristane-induced lupus. Rheumatology (Oxford) 2007;46:1405&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">17576695</ArticleId></ArticleIdList></Reference><Reference><Citation>Alperovich G, Rama I, Lloberas N, Franquesa M, Poveda R, Gom&#xe0; M, Herrero-Fresneda I, Cruzado JM, Bola&#xf1;os N, Carrera M, et al. New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus. 2007;16:18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">17283580</ArticleId></ArticleIdList></Reference><Reference><Citation>Spurr AR. A low-viscosity epoxy resin embedding medium for electron microscopy. J. Ultrastruct. Res. 1969;26:31&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">4887011</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher DE, Reeves WH, Conner GE, Blobel G, Kunkel HG. Pulse labeling of small nuclear ribonucleoproteins in vivo reveals distinct patterns of antigen recognition by human autoimmune antibodies. Proc. Natl. Acad. Sci. USA. 1984;81:3185&#x2013;3189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC345246</ArticleId><ArticleId IdType="pubmed">6203115</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Reino JJ, Mart&#xed;nez-Laso J, Vicario JL, Paz-Artal E, Arag&#xf3;n A, Mart&#xed;n-Villa JM, De Juan MD, P&#xe9;rez-Aciego P, Arnaiz-Villena A. Immunogenetics of systemic lupus erythematosus in Spanish patients: differential HLA markers. Immunobiology. 1991;182:465&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">1916886</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeazzi M, Sebastiani GD, Morozzi G, Carcassi C, Ferrara GB, Scorza R, Cervera R, de Ramon Garrido E, Fernandez-Nebro A, Houssiau F, et al. European Concertee Action on the immunogenetics of SLE. HLA class II DNA typing in a large series of European patients with systemic lupus erythematosus: correlations with clinical and autoantibody subsets. Medicine (Baltimore) 2002;81:169&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">11997714</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekker-Mendez C, Yamamoto-Furusho JK, Vargas-Alarc&#xf3;n G, Ize-Ludlow D, Alcocer-Varela J, Granados J. Haplotype distribution of class II MHC genes in Mexican patients with systemic lupus erythematosus. Scand. J. Rheumatol. 1998;27:373&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">9808402</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Villa JM, Mart&#xed;nez-Laso J, Moreno-Pelayo MA, Castro-Panete MJ, Mart&#xed;nez-Quiles N, Alvarez M, de Juan MD, G&#xf3;mez-Reino JJ, Arnaiz-Villena A. Differential contribution of HLA-DR, DQ, and TAP2 alleles to systemic lupus erythematosus susceptibility in Spanish patients: role of TAP2*01 alleles in Ro autoantibody production. Ann. Rheum. Dis. 1998;57:214&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1752585</ArticleId><ArticleId IdType="pubmed">9709177</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankarkumar U, Ghosh K, Badakere SS, Mohanty D. HLA-DRB1*03 and DQB1*0302 associations in a subset of patients severely affected with systemic lupus erythematosus from western India. Ann. Rheum. Dis. 2003;62:92&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1754282</ArticleId><ArticleId IdType="pubmed">12480686</ArticleId></ArticleIdList></Reference><Reference><Citation>Barcellos LF, May SL, Ramsay PP, Quach HL, Lane JA, Nititham J, Noble JA, Taylor KE, Quach DL, Chung SA, et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet. 2009;5:e1000696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758598</ArticleId><ArticleId IdType="pubmed">19851445</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley JB, Sestak AL, Willis LG, Fu SM, Hansen JA, Reichlin M. A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum. 1989;32:826&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">2787639</ArticleId></ArticleIdList></Reference><Reference><Citation>Schur PH, Marcus-Bagley D, Awdeh Z, Yunis EJ, Alper CA. The effect of ethnicity on major histocompatibility complex complement allotypes and extended haplotypes in patients with systemic lupus erythematosus. Arthritis Rheum. 1990;33:985&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pubmed">2369433</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando MM, Stevens CR, Sabeti PC, Walsh EC, McWhinnie AJ, Shah A, Green T, Rioux JD, Vyse TJ. Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genet. 2007;3:e192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2065882</ArticleId><ArticleId IdType="pubmed">17997607</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris DL, Fernando MM, Taylor KE, Chung SA, Nititham J, Alarc&#xf3;n-Riquelme ME, Barcellos LF, Behrens TW, Cotsapas C, Gaffney PM, et al. MHC associations with clinical and autoantibody manifestations in European SLE. Genes Immun. 2014;15:210&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102853</ArticleId><ArticleId IdType="pubmed">24598797</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu Z, Zhang P, Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int. J. Rheum. Dis. 2015;18:17&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">25546242</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung SA, Brown EE, Williams AH, Ramos PS, Berthier CC, Bhangale T, Alarcon-Riquelme ME, Behrens TW, Criswell LA, Graham DC, et al. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J. Am. Soc. Nephrol. 2014;25:2859&#x2013;2870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243339</ArticleId><ArticleId IdType="pubmed">24925725</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor KE, Chung SA, Graham RR, Ortmann WA, Lee AT, Langefeld CD, Jacob CO, Kamboh MI, Alarc&#xf3;n-Riquelme ME, Tsao BP, et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 2011;7:e1001311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040652</ArticleId><ArticleId IdType="pubmed">21379322</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C, Deshmukh US, Gaskin F, Bagavant H, Hanson J, David CS, Fu SM. Differential responses to Smith D autoantigen by mice with HLA-DR and HLA-DQ transgenes: dominant responses by HLA-DR3 transgenic mice with diversification of autoantibodies to small nuclear ribonucleoprotein, double-stranded DNA, and nuclear antigens. J. Immunol. 2010;184:1085&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842881</ArticleId><ArticleId IdType="pubmed">20007529</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg RA, Craven SY, Warren RW, Cohen PL. Stochastic control of anti-Sm autoantibodies in MRL/Mp-lpr/lpr mice. J. Clin. Invest. 1987;80:691&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC442292</ArticleId><ArticleId IdType="pubmed">3624484</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemekasten G, Kawald A, Weiss C, Meine A, Marell J, Klein R, Hocher B, Meisel C, Hausdorf G, Manz R, et al. Strong acceleration of murine lupus by injection of the SmD1(83-119) peptide. Arthritis Rheum. 2001;44:2435&#x2013;2445.</Citation><ArticleIdList><ArticleId IdType="pubmed">11665986</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemekasten G, Langnickel D, Ebling FM, Karpouzas G, Kalsi J, Herberth G, Tsao BP, Henklein P, Langer S, Burmester GR, et al. Identification and characterization of SmD183-119-reactive T cells that provide T cell help for pathogenic anti-double-stranded DNA antibodies. Arthritis Rheum. 2003;48:475&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">12571858</ArticleId></ArticleIdList></Reference><Reference><Citation>Janwityanuchit S, Verasertniyom O, Vanichapuntu M, Vatanasuk M. Anti-Sm: its predictive value in systemic lupus erythematosus. Clin. Rheumatol. 1993;12:350&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">8258234</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty GA, Harley JB, Reichlin M. A distinctive autoantibody profile in black female patients with lupus nephritis. Arthritis Rheum. 1993;36:1560&#x2013;1565.</Citation><ArticleIdList><ArticleId IdType="pubmed">8240432</ArticleId></ArticleIdList></Reference><Reference><Citation>Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I, Khamashta MA, D&#x2019;Cruz D, Hughes GR. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann. Rheum. Dis. 2003;62:556&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1754557</ArticleId><ArticleId IdType="pubmed">12759294</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannik M, Merrill CE, Stamps LD, Wener MH. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J. Rheumatol. 2003;30:1495&#x2013;1504.</Citation><ArticleIdList><ArticleId IdType="pubmed">12858447</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruschi M, Sinico RA, Moroni G, Pratesi F, Migliorini P, Galetti M, Murtas C, Tincani A, Madaio M, Radice A, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo: &#x3b1;-enolase and annexin AI. J. Am. Soc. Nephrol. 2014;25:2483&#x2013;2498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4214525</ArticleId><ArticleId IdType="pubmed">24790181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruschi M, Galetti M, Sinico RA, Moroni G, Bonanni A, Radice A, Tincani A, Pratesi F, Migliorini P, Murtas C, et al. Glomerular autoimmune muticomponents of human lupus nephritis in vivo (2): planted antigens. J. Am. Soc. Nephrol. 2015;26:1905&#x2013;1924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4520170</ArticleId><ArticleId IdType="pubmed">25398787</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>